March 2024
Volume 13, Issue 3
Open Access
Erratum  |   March 2024
Erratum in: Establishment of a Beagle Dog Model of Dry Eye Disease
Translational Vision Science & Technology March 2024, Vol.13, 27. doi:https://doi.org/10.1167/tvst.13.3.27
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum in: Establishment of a Beagle Dog Model of Dry Eye Disease. Trans. Vis. Sci. Tech. 2024;13(3):27. https://doi.org/10.1167/tvst.13.3.27.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Erratum in: “Establishment of a Beagle Dog Model of Dry Eye Disease” by Zhi-zheng Li, Yan-ping Zou, Hui Zhu, Wei-zhen Zeng, Yi Ding, Jia-zeng Su, and Guang-yan Yu (Transl Vis Sci Technol. 2023;12(1):2), https://doi.org/10.1167/tvst.12.1.2
In the version of this article originally published, the investigators provided a brief description of the postoperative care regimen during the surgical induction of dry eye disease (DED). To provide greater clarification on the pain management of animals carried out during the study and address concerns by Ofri et al.,1 the authors2 have made additions to the Methods section. Three references have also been added. These changes do not affect the conclusions of the article. The authors apologize for any confusion the initial oversight may have caused. 
The following changes have been made to the article online. 
The following text has been added to the end of the first paragraph in the Methods section: “The animals were maintained and survival surgeries were performed at the Peking University Laboratory Animal Center, where adherence to the ARVO Statement for Use of Animals in Ophthalmic and Vision Research was observed and enforced.” 
The following paragraph has been added at the end of the Surgical Induction of DED section in the Methods: 
“For pain management, immediately after the surgical procedures, daily analgesics (Carprofen, Zoetis, Inc., Chicago, IL, USA; 4 mg/kg) were administered orally for 3 days. Based on the consensus report and clinical guidelines,26 neither topical nor systemic analgesics are included in the current treatment regimen for patients with DED. Owing to a lack of evidence-based research on the nature of DED-induced pain and effective analgesic to alleviate it,27,28 continued analgesics administration was not adopted during the subsequent observation period. However, supportive ocular surface care such as cleanup of excess discharge was performed once daily for the first month after surgery and once weekly thereafter. At the end of the observation period, subjects received immediate intervention with salivary gland transplantation.” 
The following References have been added: 
  • 26. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575–628.
  • 27. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II Pain and Sensation Report. Ocul Surf. 2017;15:404–437.
  • 28. Tei Y, Mikami Y, Ito M, et al. Pathogenic mechanism of dry eye-induced chronic ocular pain and a mechanism-based therapeutic approach. Invest Ophthalmol Vis Sci. 2022;63:7.
References
Ofri R, Millichamp NJ, Keller C, et al. Concerns about a dog model of dry eye disease. Transl Vis Sci Technol. 2024; 13(3): 28, doi:10.1167/tvst.13.3.28. [PubMed]
Li Z, Zou Y, Zhu H, et al. Author response: Concerns about a dog model of dry eye disease. Transl Vis Sci Technol. 2024; 13(3): 26, doi:10.1167/tvst.13.3.26. [CrossRef] [PubMed]
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×